Korro Bio Files for KRRO-121 Phase 1/2 Trial in Australia
KRRO has more than doubled off its 52-week low of $5.204.
Summary
Korro Bio announced submission of a clinical trial application in Australia for KRRO-121, its lead RNA editing candidate for urea cycle disorders, initiating the first-in-human Phase 1/2 study.
Key Events · Product Development and Regulatory · KRRO
-
KRRO-121 Trial Application Submitted
An application has been submitted to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121 in urea cycle disorders.
-
Trial Design and Objectives
The Phase 1/2 trial will evaluate safety and tolerability of escalating doses, pharmacokinetics, and effect in healthy volunteers and patients with urea cycle disorders.
-
Regulatory Milestone
This submission is the first regulatory step toward clinical development of KRRO-121, consistent with prior guidance for a first-in-human trial in 2H 2026.
-
ClinicalTrials.gov Identifier
The trial is registered under NCT 07773246.
Analysis · KRRO · Life Sciences
A first regulatory step toward clinical validation of its lead program has been taken, with an application submitted to the Australian Alfred Health Human Ethics Committee to begin a first-in-human Phase 1/2 trial for KRRO-121, the company's RNA editing candidate for urea cycle disorders. The trial will assess safety, tolerability, pharmacokinetics, and effect in healthy volunteers and UCD patients. While the submission does not guarantee approval, it marks a concrete milestone in the pipeline and aligns with prior guidance that KRRO-121 would enter the clinic in 2H 2026.
At the time of this filing, KRRO was trading at $13.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.4M. The 52-week trading range was $5.20 to $55.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.